These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 22428857

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H, Matsumaru N, Tsukamoto K.
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Economics of new oncology drug development.
    DiMasi JA, Grabowski HG.
    J Clin Oncol; 2007 Jan 10; 25(2):209-16. PubMed ID: 17210942
    [Abstract] [Full Text] [Related]

  • 5. A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers.
    Yamashita K, Kaneko M, Narukawa M.
    Clin Pharmacol Ther; 2019 Jan 10; 105(1):153-160. PubMed ID: 29882302
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ultimate fate of oncology drugs approved by the us food and drug administration without a randomized Trial.
    Tsimberidou AM, Braiteh F, Stewart DJ, Kurzrock R.
    J Clin Oncol; 2009 Dec 20; 27(36):6243-50. PubMed ID: 19826112
    [Abstract] [Full Text] [Related]

  • 8. Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study.
    Maeda H, Hara A, Ofuchi M, Shingai R, Misumi T, Murai Y.
    Clin Transl Sci; 2023 Dec 20; 16(12):2665-2674. PubMed ID: 37815272
    [Abstract] [Full Text] [Related]

  • 9. Analysis of the success rates of new drug development in Japan and the lag behind the US.
    Hirai Y, Yamanaka Y, Kusama M, Ishibashi T, Sugiyama Y, Ono S.
    Health Policy; 2012 Mar 20; 104(3):241-6. PubMed ID: 22172246
    [Abstract] [Full Text] [Related]

  • 10. Oncology drug lag in Japan: has it improved over the last decade?
    Tachibana Y, Narukawa M.
    Int J Clin Oncol; 2023 Nov 20; 28(11):1451-1460. PubMed ID: 37561368
    [Abstract] [Full Text] [Related]

  • 11. Relationship between drug lag and factors associated with clinical trials in Japan.
    Ohwaki K, Nakabayashi T.
    J Clin Pharm Ther; 2014 Dec 20; 39(6):649-52. PubMed ID: 25200123
    [Abstract] [Full Text] [Related]

  • 12. Approval of new drugs 1999-2007: comparison of the US, the EU and Japan situations.
    Tsuji K, Tsutani K.
    J Clin Pharm Ther; 2010 Jun 20; 35(3):289-301. PubMed ID: 20848767
    [Abstract] [Full Text] [Related]

  • 13. Regulatory review time for approval of oncology drugs in Japan between 2001 and 2014. Considerations of changes, factors that affect review time, and difference with the United States.
    Maeda H, Kurokawa T.
    J Clin Pharmacol; 2015 May 20; 55(5):481-9. PubMed ID: 25560978
    [Abstract] [Full Text] [Related]

  • 14. Approval of new biopharmaceuticals 1999-2006: comparison of the US, EU and Japan situations.
    Tsuji K, Tsutani K.
    Eur J Pharm Biopharm; 2008 Mar 20; 68(3):496-502. PubMed ID: 17884403
    [Abstract] [Full Text] [Related]

  • 15. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries.
    Maeda H, Kurokawa T.
    Invest New Drugs; 2014 Aug 20; 32(4):661-9. PubMed ID: 24615632
    [Abstract] [Full Text] [Related]

  • 16. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 20; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic indications in oncology: emerging features and regulatory dynamics.
    Tafuri G, Leufkens HG, Laing R, Trotta F.
    Eur J Cancer; 2010 Feb 20; 46(3):471-5. PubMed ID: 20056536
    [Abstract] [Full Text] [Related]

  • 18. Delays in new drug applications in Japan and industrial R&D strategies.
    Hirai Y, Kinoshita H, Kusama M, Yasuda K, Sugiyama Y, Ono S.
    Clin Pharmacol Ther; 2010 Feb 20; 87(2):212-8. PubMed ID: 19940847
    [Abstract] [Full Text] [Related]

  • 19. The notorious "drug lag" for oncology drugs in Japan.
    Yonemori K, Hirakawa A, Ando M, Hirata T, Yunokawa M, Shimizu C, Katsumata N, Tamura K, Fujiwara Y.
    Invest New Drugs; 2011 Aug 20; 29(4):706-12. PubMed ID: 21286780
    [Abstract] [Full Text] [Related]

  • 20. Exploratory Analysis of Drug Lag in New Oncology Drugs Between Japan and the US.
    Maki A, Narukawa M.
    Ther Innov Regul Sci; 2023 Jul 20; 57(4):671-677. PubMed ID: 36966205
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.